1026785-59-0

Storage:at -20

Biologieal

VX-222 (HCV Infection) is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection. While the protease inhibitors (telaprevir and boceprevir) are the directly-targeted anti-HCV agents furthest along in the development pipeline, HCV polymerase - an enzyme responsible for copying viral genetic material-is also a promising target. VX-222 is a novel non-nucleoside HCV NS5B polymerase inhibitor with potent in vitro activity. [1]

Reference

[1] 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010).2010 April 14-18; Vienna, Austria